This is the Ada Health pitch deck to raise a $90m series-b round in 2021.
About
Ada is a global health company founded by doctors, scientists, and industry pioneers to create new possibilities for personal health. Ada’s core system connects medical knowledge with intelligent technology to help all people actively manage their health and medical professionals to deliver effective care. Ada is proud to collaborate with leading health systems and global non-profit organizations to carry out this vision.
Ada Health was founded in 2011 and is based in Berlin, Germany.
The funding is led by Leaps by Bayer, the impact investment arm of German pharmaceutical giant Bayer. Ada Health uses artificial intelligence to assess patients’ health, helping them identify and understand their symptoms.
Investment in telehealth startups has steadily ticked up over the last five years.
In the US, startups raised $7.8 billion across 710 deals in 2019, up from $7.3 billion the prior year, according to Pitchbook. And health tech is the third-largest sector for venture capital investment in Europe, attracting $4.2 billion in 2020, according to figures from Atomico. It was also the fastest-growing segment for investment in 2020, the same report showed, marking heightened investor interest during the pandemic.
“Our growth is part of the wider trend, digital health has come of age and the COVID-19 pandemic has accelerated a process that was already on the way,” Ada CEO Daniel Nathrath said. “What Ada does is give people a chance 24/7 to see what’s causing health issues and advice on what to do next.”
Ada says it has more than 11 million users worldwide and has completed over 23 million assessments since its launch in 2016. Nathrath told Insider the company’s ambition was to reach 1 billion people.
Funding will go towards product improvements and further expanding the company’s presence in the US where Ada says it has 2 million users. The company will expand its UK and US teams with the new capital.
Other investors in the round included Samsung Catalyst Fund, Vitruvian Partners, Inteligo Bank, F4 and Mutschler Ventures. Dr. Jürgen Eckhardt, head of Leaps by Bayer, praised Ada’s “high levels of clinical accuracy” and “medical rigor.”
Funding rounds
| Announced Date | Transaction Name | Number of Investors | Money Raised | Lead Investors |
| May 27, 2021 | Series B – Ada Health | 6 | €74M | Leaps by Bayer |
| Oct 31, 2017 | Series A – Ada Health | 4 | €40M |
Vitruvian Partners
|
| Jul 1, 2015 | Grant – Ada Health | 1 | €2.4M | — |
| Oct 1, 2011 | Angel Round – Ada Health | — | $20M | — |
Pitch deck review summary
Slide by slide review
Deck Collection
See the rest of the collection here:
Comments (0)
There are no comments yet :(